Baxter Chooses Halozyme Again; Firms Collaborate On SC IVIG

Halozyme Therapeutics Inc. could earn up to $47 million in its latest deal with Baxter International Inc., which aims to develop a subcutaneous version of Gammagard, Baxter's intravenous immune globulin (IVIG) product approved for primary immunodeficiency disorders. (BioWorld Today)